Table 2 Outcomes after 48 weeks of boosted protease inhibitor regimens
Outcomes | Week 48 | |||
|---|---|---|---|---|
Total | Single –boosted PI | Double-boosted PI | P-value | |
Median (IQR) CD4% | 20 (15–26) (n = 200) | 24 (18–30) (n = 83) | 17 (14–22) (n = 117) | < 0.001 |
Median(IQR) CD4% gain | 10(1–7) (n = 199) | 7(2–12) (n = 83) | 10(6–15) (n = 116) | 0.002 |
% with HIV RNA < 400 copies/ml | 81.3 (n = 144) | 83.1 (n = 65) | 79.8 (n = 79) | 0.610 |
% with HIV RNA < 50 copies/ml | 63.0 (n = 138) | 76.6 (n = 64) | 51.4 (n = 74) | 0.002 |
% with Cholesterol > 200 mg/dl | 42.5 (n = 162) | 34.3 (n = 70) | 48.9 (n = 92) | 0.062 |
% with Triglyceride > 150 mg/dl | 62.4 (n = 157) | 61.8 (n = 68) | 62.9 (n = 89) | 0.882 |
% with Low density lipoprotein > 130 mg/dl | 31.8 (n = 88) | 16.2 (n = 37) | 43.1 (n = 51) | 0.007 |